EHC

SEC source: 0000785161-26-000024 · form4.xml · nonDerivative · entry 1

Hayes Cain A · CIK 0001834471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 457

F1 · shares: Award of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

SEC source: 0000785161-26-000016 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,659

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000014 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,839

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000012 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,839

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000010 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,912

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000008 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,259

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000004 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,182

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.82 to $102.90, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000004 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,913

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000006 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,169

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000002 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,450

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.79 to $103.08, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000002 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,104

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000110 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,631

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000108 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,904

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on October 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.20 to $123.21, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-25-000108 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,681

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000106 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,752

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000104 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,752

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000100 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,085

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on October 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.19 to $123.24, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-25-000100 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,797

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000102 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,895

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000098 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,219

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000096 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,141

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-020999 · form4.xml · nonDerivative · entry 1

Tuer Patrick William · CIK 0002065822 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,846

SEC source: 0001127602-25-020840 · form4.xml · nonDerivative · entry 2

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By irrevocable trust

Disclosed balance after: 27,480

F1 · kind: This transaction involved the reporting person's spouse transferring shares of EHC common stock to a trust in which the reporting person is a beneficiary.

SEC source: 0001127602-25-020840 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 37,749

F1 · kind: This transaction involved the reporting person's spouse transferring shares of EHC common stock to a trust in which the reporting person is a beneficiary.

F2 · balance_after: The reporting person disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001127602-25-019258 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,781

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on July 15, 2025

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.82 to $106.89, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-019245 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,674

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on July 15, 2025

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.48 to $106.68, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-019258 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,448

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019255 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,186

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019251 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,764

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019253 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,881

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019249 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,679

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019247 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,679

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019243 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,608

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019245 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,414

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019238 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,118

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-015049 · form4.xml · derivative · entry 6

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 62,078 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F2 · derivative.underlying_shares: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-25-015049 · form4.xml · derivative · entry 5

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 56,306 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F2 · derivative.underlying_shares: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-25-015049 · form4.xml · nonDerivative · entry 4

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 527,070

F1 · price: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.03 to $121.96, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-015049 · form4.xml · nonDerivative · entry 3

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 645,360

SEC source: 0001127602-25-015049 · form4.xml · nonDerivative · entry 2

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 645,454

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-25-015049 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 583,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-25-014409 · form4.xml · nonDerivative · entry 1

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,489

F1 · kind: Represents shares of Common Stock that the reporting person donated as a gift to a donor advised fund administered by Schwab.

SEC source: 0001127602-25-013555 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,958.061

SEC source: 0001127602-25-013143 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,584

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-013139 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,406

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-013136 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,605

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-013128 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,740

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-013132 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,605

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-013124 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,431

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-013126 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,866

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.